1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
Onychomycosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Onychomycosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • April 2021
  • 126 pages
  • ID: 6062858
  • Format: PDF
  • Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

The onychomycosis market estimated to be valued at USD USD 2730.72 million in 2020 and is expected to reach approximately USD 3781.42 million in 2026, registering a CAGR of nearly 5.75% during the forecast period.

Prior to the COVID-19 pandemic, clinical examination, dermoscopy, and mycological examination were recommended for all patients with suspected onychomycosis. However, with the spread of the COVID-19 pandemic, non-urgent in-person visits are being deferred, and telemedicine may be utilized to address some aspects of onychomycosis diagnosis and treatment. Telemedicine may be appropriately utilized to assess patients with suspected onychomycosis, but it is better optimized for patients with prior mycological confirmation.

Hence, the market is expected to witness a short-term disruption due to the COVID-19 pandemic. However, the revenue growth rate is expected to recover during the forecast period, and the global onychomycosis market is estimated to digit growth trajectory.

Onychomycosis, also known as tinea unguium, is a fungal infection of the fingernails or toenails that may involve any component of the nail unit, including the matrix, bed, or plate. This may cause pain, disfigurement, and discomfort and may produce serious issues, and results in reducing the quality of life. Onychomycosis is of different types such as superficial onychomycosis, distal and lateral subungual onychomycosis, proximal subungual onychomycosis, endonyx onychomycosis, and total dystrophic onychomycosis. Onychomycosis accounts for one-third of fungal skin infections because only about one-half of nail dystrophies are caused by fungus.

Increasing the geriatric population, rising prevalence of onychomycosis, and diabetic population worldwide and growing awareness about the potential threats of onychomycosis are the key driving factors in the onychomycosis treatment market.In addition, according to the United Nations Department of Economics and Social’s 2019 report, by 2050, 1 in 6 people around the world will be over the age of 65 (16%), up from 1 in 11 people in 2019 (9%). By 2050, 1 in 4 persons living in Europe and North America could be aged 65 years or above. The number of persons aged 80 years and above is projected to triple, from 143 million in 2019 to approximately 426 million in 2050.?

Key Market Trends
The Drugs Segment is Expected to Hold a Major Market Share in the Onychomycosis Treatment Market

Some of the drugs available for the treatment of onychomycosis are terbinafine, ciclopirox, Jublia, fluconazole, Penlac, Ciclodan, ketoconazole, Sporanox, itraconazole, Kerydin, efinaconazole, griseofulvin, and so on. For onychomycosis treatment, drugs remain the first-line choice of treatment with major market share owing to a consistently high success rate.

As per Elewski and Charif onychomycosis report, states that approximately 40% of the elderly population have onychomycosis. Moreover, a reduction in nail growth rate ranges from about 40% to 60% in persons more than 65 years of age. Furthermore, onychomycosis affects approximately 2% to 26% of different populations globally. Moreover, less than 30% of infected individuals with onychomycosis seek medical advice or treatment in developed countries.

The drugs segment holds a significant market share in the onychomycosis treatment market and is anticipated to show a similar trend over the forecast period due to the highly effective and easy availability of the products. In February 2019, Moberg Pharma entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015, a new topical treatment of onychomycosis based on Moberg’s patented proprietary formulation of terbinafine. Bayer will be marketing, distributing, and selling MOB-015 in Europe upon completion of Phase III clinical development and registration.

Morover, with the COVID 19 pandemic, distribution of the drugs has been disrupeted all over the world due to the supply chain disruptions and expected to have impact in 2020, however, in late 2020 , 2021 and further years, market is for onychomycosis expected to recover and expected to show positive growth over the period.

North America is Expected to Hold a Significant Share in the Market in the Forecast Period

North America is expected to hold a major market share in the global onychomycosis treatment market due to high drug costs, rising geriatric population, increasing prevalence of onychomycosis, and diabetic patient population in this region. According to the United States Census Bureau 2019 Population Estimates, the 65-and-older population grew by 3.2% (1,688,924) from 2018 to 2019 to reach over 54 million. In people aged 65 years and older, the prevalence of diabetes was found to be 26.8% (total diabetes prevalence).

The reasons for the age-related increase in onychomycosis include a variety of factors, like repeated nail trauma, poor peripheral circulation, diabetes, suboptimal immune function, longer exposure to pathogenic fungi, inactivity, or the inability to cut the toenails or maintain good foot care. Various strategies, such as research and development, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position.

In October 2020, United States-headquartered Pfizer Inc. announced that it had begun clinical studies concerning onychomycosis. The first one involved a study in determining whether the AN2690 topical solution is an effective treatment for onychomycosis of the toenail. The second one was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in both children and adolescents.
On the other hand COVID 19 pandemic has resulted decreased diagnosis and impacted the sales revenue of drugs and other treatment methods for onychomycosis as there is focus of hospitals and primary care centers for COVID 19 patients .

Competitive Landscape
The onychomycosis treatment market is fragmented competitive and consists of several major players. Companies are focusing on developments, collaborations, new product launches and to strengthen their market position. For instance, In April 2020, the United States Food and Drug Administration expanded the approval of Jublia manufactured by Bausch Health. Jublia is a topical solution use in the treatment of onychomycosis of the toenail(s) in patients aged six years and above.

Some of the players which are currently dominating the market are Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), Galderma SA, Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Medimetriks Pharmaceuticals Inc., and Lumenis Ltd.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Onychomycosis (Tinea Unguium) (Infectious Disease) - Drugs in Development, 2021

  • $ 2000
  • March 2021
  • 81 pages

Onychomycosis (Tinea Unguium) (Infectious Disease) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis - Drugs in Development, 2021, provides ...

  • World
  • South Africa
  • Antifungal
  • Pharmaceutical
  • Industry analysis
  • Dropout Rate
  • Drug Approval

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on